Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Devices
P/S (TTM)
3.9
Apollo Endosurgery, Inc. is a medical technology firm specializing in the creation, development, and commercialization of advanced medical instruments. Among its products are the OverStitch and OverStitch Sx Endoscopic Suturing Systems, which empower physicians to perform advanced endoscopic procedures by suturing and securing tissue approximation via a flexible endoscope. The company also features the Orbera intragastric balloon system, available under brands such as Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System. This system aids in weight management by decreasing stomach capacity and slowing gastric emptying, thereby encouraging reduced food intake. Additionally, it provides the X-Tack Endoscopic HeliX Tacking System, a suture-based device designed for repairing defects in both the upper and lower gastrointestinal tract. Its medical solutions are distributed to various healthcare providers, including hospitals, outpatient surgical centers, clinics, and individual physicians, across the United States, Australia, Costa Rica, and several European nations. Founded in 2005, Apollo Endosurgery, Inc. maintains its headquarters in Austin, Texas.
www.endura.comNo one on the platform currently holds APEN.
No tracked institution reports a position in APEN as of their last filing.
| Execution date | Ratio |
|---|---|
| 2016-06-13 | 1-for-14reverse |
No one on the platform has traded APEN yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Analyst estimates unavailable for this ticker.
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2023-03-30 | $-0.21 | $0.23 | +209.5% |
| 2022-11-01 | $-0.23 | $-0.28 | -21.7% |
| 2022-08-02 | $-0.22 | $-0.26 | -18.2% |
| 2022-05-03 | $-0.20 | $-0.21 | -5.0% |
| 2022-02-22 | $-0.19 | $-0.27 | -42.1% |
| 2021-11-01 | $-0.28 | $-0.23 | +17.9% |
| 2021-08-03 | $-0.20 | $-0.11 | +45.0% |
| 2021-05-04 | $-0.22 | $-0.17 | +22.7% |
| $83M |
| — |
| PETVPetVivo Holdings, Inc. | $0.69 | +1.47% | $26M | — |
| SSKNSTRATA Skin Sciences, Inc. | $0.01 | +0.00% | $23251 | — |
Source: Financial Modeling Prep · peers by sector/industry
$APEN honestly, i'm liking what i'm seeing
View on StockTwits ↗$APEN eps rev guidance margins matter valuation dilution risk
View on StockTwits ↗$SCPH https://whalewisdom.com/filer/lytton-laurence-w I remember reading about this guy a while back - likely due to a comment on the Yahoo Finance board about him buying a significant stake in SCPH. According to his most recent 13G filing in November, he owns 2,944,942 shares. I'm not sure what his cost basis was for his purchase of $apen , but I'm guessing he purchased it before the acquisition and may have done well on that buy. I'm hoping we see SCPH recover soon. I'm looking at this as a double from these levels within the next 6 months. I believe that's a conservative valuation. If quarterly revenues are sticky and growing, then this could very well be a multi bagger in the next 12 months, if not a takeover candidate as well. Hoping for a strong recovery in the coming days and weeks... Best wishes, 🥩
View on StockTwits ↗$APEN was analyzed by 11 analysts. The buy consensus is at 76%. So analysts seem to be mildly confident about $APEN. https://www.chartmill.com/stock/quote/APEN/analyst-ratings?utm_source=stocktwits&utm_medium=ANALYST&utm_content=APEN&utm_campaign=social_tracking
View on StockTwits ↗$APEN was analyzed by 11 analysts. The buy consensus is at 76%. So analysts seem to be mildly confident about $APEN. https://www.chartmill.com/stock/quote/APEN/analyst-ratings?utm_source=stocktwits&utm_medium=ANALYST&utm_content=APEN&utm_campaign=social_tracking
View on StockTwits ↗$APEN is currently trading near its 52 week high, which is a good sign, certainly when compared to the index. https://www.chartmill.com/stock/quote/APEN/technical-analysis?key=5d9abe1e-c147-4bc5-b450-c829cfd41e68&utm_source=stocktwits&utm_medium=TA&utm_content=APEN&utm_campaign=social_tracking
View on StockTwits ↗$APEN has an average volume of 1448780. This is a good sign as it is always nice to have a liquid stock. https://www.chartmill.com/stock/quote/APEN/technical-analysis?key=5d9abe1e-c147-4bc5-b450-c829cfd41e68&utm_source=stocktwits&utm_medium=TA&utm_content=APEN&utm_campaign=social_tracking
View on StockTwits ↗$APEN [15s. delayed] filed SEC form 4: Director Bankes Jeannette: Disposed 17,641 of Common Stock on 2023-04-04, decreased holding by 100 https://s.flashalert.me/RRRTM
View on StockTwits ↗$APEN [15s. delayed] filed SEC form 4: Director BARR JOHN R: Disposed 44,082 of Common Stock on 2023-04-04, decreased holding by 100% to https://s.flashalert.me/ecPNC
View on StockTwits ↗$APEN [15s. delayed] filed SEC form 4: President and CEO McKhann Chas: Disposed 689,880 of Common Stock on 2023-04-04, decreased holding https://s.flashalert.me/NnzfLE
View on StockTwits ↗$APEN [15s. delayed] filed SEC form 4: Director O'KEEFE SHARON: Disposed 35,604 of Common Stock on 2023-04-04, decreased holding by 100% https://s.flashalert.me/teY6f
View on StockTwits ↗$APEN [15s. delayed] filed SEC form 4: Director McClellan William D. Jr.: Disposed 41,249 of Common Stock on 2023-04-04, decreased holdin https://s.flashalert.me/pl0iR
View on StockTwits ↗$APEN [15s. delayed] filed SEC form 4: EVP, Operations Molesphini John J: Disposed 92,626 of Common Stock on 2023-04-04, decreased holdin https://s.flashalert.me/49495a
View on StockTwits ↗$APEN [15s. delayed] filed SEC form 4: Chief Medical Officer Gostout Christopher J.: Disposed 90,267 of Common Stock on 2023-04-04, decre https://s.flashalert.me/rW1Hi
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.